Protalix BioTherapeutics (PLX) Amortization of Deferred Charges (2013 - 2023)

Protalix BioTherapeutics' Amortization of Deferred Charges history runs 11 years deep, the most recent figure standing at $59000.0 for Q4 2023.

• In Q4 2023, Amortization of Deferred Charges fell 22.37% year-over-year to $59000.0; the TTM figure through Dec 2023 stood at $267000.0 (down 11.0% YoY), while the FY2023 annual figure was $267000.0, down 11.0% from the prior year.
• Amortization of Deferred Charges was $59000.0 for Q4 2023 at Protalix BioTherapeutics, down from $60000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $983000.0 in Q2 2021 to a low of $59000.0 in Q4 2023.
• Historically, Amortization of Deferred Charges has averaged $485050.0 across 5 years, with a median of $672500.0 in 2019.
• The sharpest annual moves came in 2020 and 2022: Amortization of Deferred Charges increased 16.48% in 2020, then slumped 92.78% in 2022.
• A 5-year view of Amortization of Deferred Charges shows it stood at $794000.0 in 2019, then climbed by 16.12% to $922000.0 in 2020, then tumbled by 88.72% to $104000.0 in 2021, then declined by 26.92% to $76000.0 in 2022, then decreased by 22.37% to $59000.0 in 2023.
• The last three Amortization of Deferred Charges figures came in at $59000.0 (Q4 2023), $60000.0 (Q3 2023), and $68000.0 (Q2 2023), per Business Quant data.